
























Trace	Amine-Associated	Receptor	1	 (TAAR1)	 is	a	G	protein-coupled	receptor	expressed	 in	 the	
mammalian	 brain	 and	 known	 to	 influence	 subcortical	 monoaminergic	 transmission.	
Monoamines,	such	as	dopamine,	play	also	an	important	role	within	the	prefrontal	cortex	(PFC)	
circuitry,	which	 is	critically	 involved	 in	high	order	cognitive	processes.	TAAR1	selective	 ligands	
have	 shown	potential	 antipsychotic,	 antidepressant	 and	pro-cognitive	effects	 in	experimental	




The	 dysregulated	 cortical	 glutamate	 transmission	 in	 TAAR1-KO	 mice	 was	 associated	 with	
aberrant	 behaviors	 in	 several	 tests,	 indicating	 a	 perseverative	 and	 impulsive	 phenotype	 of	
mutants.	 Conversely,	 pharmacological	 activation	 of	 TAAR1	 with	 selective	 agonists	 reduced	
premature	impulsive	responses	observed	in	the	fixed-interval	conditioning	schedule	in	normal	
mice.	 Our	 study	 indicates	 that	 TAAR1	 plays	 an	 important	 role	 in	 the	 modulation	 of	 NMDA	







Trace	Amine-Associated	Receptor	1	 (TAAR1)	 is	 a	G	protein-coupled	 receptor	 (GPCR)	 found	 in	
several	regions	of	the	mammalian	brain	with	the	highest	expression	observed	in	the	subcortical	
monoaminergic	nuclei,	such	as	the	ventral	tegmental	area	(VTA)	and	the	dorsal	raphe,	whereas	
low	 levels	 are	 detected	 in	 the	 striatum	and	 several	 other	 brain	 areas	 (Borowsky	 et	 al,	 2001;	
Bunzow	et	al,	2001;	Di	Cara	et	al,	2011;	Lindemann	et	al,	2008).	Recently,	TAAR1	functions	have	
been	extensively	characterized,	with	particular	attention	paid	 to	 its	 role	 in	 the	modulation	of	
the	midbrain	dopamine	system	and	 its	possible	 implications	 in	psychiatric	diseases	(Borowsky	
et	al,	2001;	Bunzow	et	al,	2001;	Leo	et	al,	2014;	Lindemann	and	Hoener,	2005;	Sotnikova	et	al,	








evidence	suggesting	a	potential	TAAR1	 involvement	 in	cognitive	 functions	 (Revel	 et	al,	2013),		
no	 studies	 evaluated	 TAAR1	 role	 in	 cortical	 regions	 so	 far.	 Recently,	 it	 has	 been	 shown	 that	
TAAR1	agonists	were	able	to	suppress	hyperactivity	in	pharmacologic	or	genetic	mouse	models	
of	 glutamate	 NMDA	 receptor	 deficiency	 and	 improved	 cognition	 in	 rats	 treated	 with	 the	
glutamate	NMDA	receptor	antagonist	phencyclidine	(PCP)	(Revel	et	al,	2013).		Intriguingly	also,	
TAAR1	agonists,	 tested	 in	phMRI	 studies	 in	mice,	 shared	a	 similar	pattern	of	brain	 activation	
with	 the	 antipsychotic	 olanzapine	with	 the	most	 prominent	 activation	 being	 observed	 in	 the	
medial	PFC	(Revel	et	al,	2013).		
Thus,	the	aim	of	this	study	was	to	investigate	the	role	of	TAAR1	in	the	prefrontal	cortex	(PFC),	a	
brain	 region	 important	 for	 cognitive	 functions.	 In	 particular,	 we	 explored	 if	 TAAR1	 might	















receptor	 expression	 and	 composition	 (Fumagalli	 et	 al,	 2012).	 The	PFC	was	homogenized	 in	 a	
glass-glass	potter	using	a	cold	buffer	containing	0.32	M	sucrose,	1	mM	Hepes	solution,	0.1	mM	
EGTA,	 and	 0.1	 mM	 PMSF,	 pH=7.4,	 in	 the	 presence	 of	 a	 complete	 set	 of	 protease	 inhibitors	
(Sigma-Aldrich,	 Milan,	 Italy)	 and	 a	 phosphatase	 inhibitor	 cocktail	 (Sigma-Aldrich).	 The	
homogenized	 tissues	 were	 centrifuged	 at	 1000	 g	 for	 10	 min;	 the	 resulting	 supernatant	 was	
centrifuged	at	9000	g	for	15	min	to	obtain	the	pellet	corresponding	to	the	crude	synaptosomal	
fraction,	which	was	resuspended	in	a	buffer	containing	20	mM	Hepes,	0.1	mM	DTT,	and	0.1	mM	
EGTA	 in	 the	 presence	 of	 a	 complete	 set	 of	 protease	 inhibitors	 and	 a	 phosphatase	 inhibitor	
cocktail.	Ten	micrograms	of	proteins	 for	each	sample	were	 run	on	a	SDS-10%	polyacrylamide	
gel	 under	 reducing	 conditions	 and	 then	 electrophoretically	 transferred	 onto	 nitrocellulose	
membranes	 (GE	 Healthcare,	 Milan,	 Italy).	 Blots	 were	 incubated	 with	 antibodies	 against	 the	
phosphorylated	forms	of	the	proteins	and	actin	was	used	as	loading	control.	Immunocomplexes	











Slices	 were	 cut	 at	 2°C	 in	 a	 solution	 containing	 (mM):	 87	 NaCl,	 25	 NaHCO3,	 2.5	 KCl,	 1.25	
NaH2PO4,	0.5	CaCl2,	7	MgCl2,	25	glucose,	and	75	sucrose	saturated	with	95%	O2	and	5%	CO2.	
After	 cutting,	 we	 recovered	 the	 slices	 for	 30-45	minutes	 at	 35°C	 and	 for	 one	 hour	 at	 room	
temperature	 in	 the	 recording	 solution.	 The	 physiological	 extracellular	 solution	 used	 for	
recordings	containing	(mM):	125	NaCl,	25	NaHCO3,	25	glucose,	2.5	KCl,	1.25	NaH2PO4,	2	CaCl2,	
and	 1	 MgCl2	 (bubbled	 with	 95%	 O2-5%	 CO2).	 For	 all	 experiments,	 we	 used	 an	 intracellular	





current-clamp	 and	 voltage-clamp	 recordings.	 All	 experiments	 were	 performed	 on	
morphologically	identified	layer	V	pyramidal	neurons.	Both	approaches	were	performed	using	a	
Multiclamp	700B	amplifier	 (Axon	 Instruments,	Molecular	Devices,	Sunnyvale	CA,	USA)	and	an	
upright	 BX51WI	 microscope	 (Olympus,	 Japan)	 equipped	 with	 Nomarski	 optics.	 For	 the	
extracellular	stimulation	of	layers	II-III,	we	used	a	bipolar	tungsten	electrode	(intensity:	50-150	
μA,	 duration:	 30	 μs)	 connected	 to	 an	 isolated	 pulse	 stimulator	 (A-M	 Systems,	 Carlsborg	WA,	
USA).	Patch	electrodes,	fabricated	from	thick	borosilicate	glasses,	were	pulled	and	fire-polished	
to	 a	 final	 resistance	 of	 5-7	 MΩ.	 Recordings	 with	 either	 leak	 currents	 >100	 pA	 or	 a	 series	
resistance	>15	MΩ	were	discarded.	Experiments	were	performed	at	22–24	°C.	For	the	isolation	
of	EPSCs	 in	 the	voltage-clamp	configuration,	Bicuculline	 (30	µM)	and	CGP58845	 (5	µM)	were	
added	to	the	extracellular	solution.	For	the	recording	of	miniature	NMDA	PSCs,	TTX	(300	nM),	












precision	 pellets	 (BioServ,	 USA).	 Each	 hole	 was	 equipped	 with	 a	 small	 LED	 with	 4	 mcd	
(millicandela)	of	luminous	intensity	that	was	remotely	controlled	via	computer,	as	it	was	for	the	
infrared	 beams	 and	 feeder.	 The	 TSE	 Systems-OBS	 software	 was	 used	 to	 design	 trial-by-trial	









this	 phase,	 the	 animals	 learned	 the	 association	between	 the	 left	 hopper	 and	 the	 feeder.	 For	
each	trial,	there	was	a	30	sec	time	limit	within	which		mice	could	receive	a	reward.	At	the	end	of	
each	 trial,	 the	 Inter	 Trial	 Interval	 (ITI)	 began,	 which	 was	 the	 sum	 of	 a	 fixed	 interval	 of	 30	
seconds	 and	 a	 random	 interval	 coming	 from	 a	 geometric	 distribution	 with	 a	 mean	 of	 60	
seconds.	This	phase	lasted	3	days.	The	Training	phase	consisted	of	a	variant	of	the	Peak	Interval	
(PI)	 timing	 procedure	 with	 80%	 Fixed-Interval	 (FI)	 trials	 and	 20%	 unreinforced	 probe	 trials.	
During	the	FI	trials,	the	mice,	as	in	the	Pre-Training	phase,	self-initiated	the	trial	by	poking	in	the	
right	 hopper	 (R),	 determining	 the	 illumination	 of	 the	 two	 holes.	 After	 two	 seconds	 (L=2	 sec)	
from	the	beginning	of	the	trials,	the	lights	switched	off,	and	only	after	ten	seconds	(T=10	sec),	a	
pellet	reward	was	delivered	in	response	to	a	NP	in	the	left	hopper	(L).	Any	NP	before	10	sec	had	
no	 consequence,	 and	 any	NP	 after	 the	 time	 limit	 (30	 sec)	was	 not	 reinforced.	 The	 ITI	 began	
after	the	release	of	the	pellet	or	at	the	end	of	the	time	limit.	Twenty	percent	of	the	probe	trials	






	Standard	 operant	 conditioning	 chambers	 (MED	 Associates,	 Inc.,	 East	 Fairfield,	 VT)	 were	
enclosed	within	 sound-attenuating	 ventilated	 cubicles,	 connected	 to	 a	 computer	 through	 an	






of	 food	and	 trained	 to	nose	poke	 for	 food	during	 two	consecutive	daily	 sessions	 (habituation	
and	magazine	training).	
Training.		
Mice	 were	 trained	 to	 nose	 poke	 for	 food	 pellet	 delivery	 according	 to	 a	 fixed-ratio	 1	 (FR1)	
schedule	of	reinforcement.	Only	one	nose	poke	in	each	box	was	active.	A	response	in	this	nose	
poke	 was	 recorded	 (correct	 response)	 and	 rewarded	 by	 the	 delivery	 of	 one	 food	 pellet.	 A	






	After	 mice	 acquired	 the	 nose-poke	 response	 (4	 days),	 the	 Fixed-Interval	 3	 sec	 (FI-3	 sec)	
schedule	was	started.	The	FI	 schedule	of	 reinforcement	 involved	delivering	 reinforcement	 for	
the	first	response	after	a	specific	period	of	time	had	elapsed.	In	the	FI-3	sec,	a	correct	response	
before	 3	 seconds	 after	 the	 previous	 delivery	 of	 reinforcement	 expired	 was	 scored	 as	 a	
premature	correct	response	but	did	not	have	programmed	consequences.	The	FI	schedule	was	
gradually	increased:	FI-5	sec,	FI-8	sec,	FI-12	sec,	FI-18	sec,	FI-24	sec,	and	FI-30	sec.	The	duration	




RO5166017	 (0.1-1.0	 mg/kg)	 and	 RO5203648	 (0.03-0.3	 mg/kg)	 were	 dissolved	 in	 saline	 with	
minimal	amounts	of	Tween	80	and	administered	i.p.	 in	a	10	ml/kg	 injection	volume.	All	drugs	




and	 the	post-reinforcement	pause	 (time	between	 last	 reinforced	 correct	nose-poke	 response	









that	 TAAR1	 could	 have	 in	 this	 region,	 we	 first	 evaluated	 its	 expression	 in	 the	 PFC	 of	 adult	
animals.	Using	RT-PCR,	we	determined	that	TAAR1	mRNA	is	 indeed	found	in	the	PFC,	with	no	
signal	 detected	 in	 TAAR1-KO	 animals	 (Fig.	 S1).	 We	 also	 measured	 TAAR1	 transcript	 in	




fluorescent	 marker	 dsRed	 was	 expressed	 under	 TAAR1	 promoter	 (Harmeier	 and	 Hoener;	
manuscript	 in	preparation).	 By	using	 this	 novel	 tool	 that	 allows	both	 the	 investigation	of	 the	
consequences	 of	 the	 lack	 of	 TAAR1	 in	 rats	 and	 the	 reliable	 mapping	 of	 TAAR1	 expression	
pattern,	we	 found	a	distinct	 fluorescent	 signal	 in	 layer	V	 cortical	neurons	 in	 general	 and	PFC	







approach	 to	 cortical	 slices.	 First,	 we	 analyzed	 the	 impact	 of	 TAAR1	 deletion	 on	 the	 intrinsic	
neuronal	 excitability	 of	 layer	 V	 pyramidal	 neurons	 in	 the	mPFC	 (Fig.	 1A,	 left	 panel).	 For	 this	
purpose,	 we	 used	 the	 patch-clamp	 method	 in	 the	 current-clamp	 configuration,	 and	 we	
measured	the	output	of	the	wild	type	(WT)	and	TAAR1-KO	mPFC	neurons	in	response	to	current	
injection	 steps	 (Fig.	 1C).	 The	 injection	 of	 current	 did	 not	 modify	 the	 action	 potential	 firing	
frequency	 in	TAAR1-KO	neurons	with	 respect	 to	WT	neurons	 (Fig.	1B,	C),	 and	 it	did	not	alter	
other	parameters	of	neuron	excitability	(Fig.	1D).	However,	the	membrane	resting	potential	in	
TAAR1-KO	 neurons	 was	 more	 depolarized	 compared	 to	 WT	 neurons	 (Fig.	 1C),	 suggesting	 a	
potential	effect	at	the	level	of	synaptic	contacts	in	the	dendritic	tree	of	these	neurons.	Synaptic	
inputs	 on	 pyramidal	 neurons	 are	 important	 for	 the	 signal	 integration	 that	 elicits	 an	 action	
potential;	 thus,	 the	 next	 step	 was	 to	 analyze,	 in	 detail,	 the	 excitatory	 synaptic	 strength	 of	
TAAR1-KO	 mPFC	 neurons.	 After	 extracellular	 stimulation	 of	 layers	 II-III	 of	 the	 mPFC	 with	 a	
bipolar	 tungsten	 electrode,	 we	 found	 that	 the	 amplitude	 of	 excitatory	 postsynaptic	 currents	
(EPSCs)	 is	 increased	 in	 TAAR1-KO	 neurons	 (Fig.	 1E,	 F).	 Moreover,	 the	 kinetics	 of	 EPSCs	 was	






To	 test	 this	 hypothesis,	we	performed	miniature	NMDA	excitatory	 postsynaptic	 currents	 and	
found	 a	 strong	 decrease	 in	 both	 the	 amplitude	 and	 the	 frequency	 of	 these	 currents	 in	 the	




NMDA	 receptors	 are	 hetero-tetramers	 formed	 from	 the	 assemblies	 of	 GluN1	 subunits	 with	
GluN2A-D	and	GluN3A/B	(Collingridge	et	al,	2013).	Thus,	to	study	the	molecular	determinants	
responsible	 for	 the	 alterations	 seen	 in	 electrophysiological	 experiments,	 we	 evaluated	 the	
expression	 of	 several	 proteins	 that	 are	 critical	 for	 glutamate	 synapses	 in	 the	 synaptosomal	
fraction	 of	 the	 PFC	 of	 adult	 WT	 animals	 and	 their	 KO	 littermates	 by	 using	 Western	 blot	
approach.	 In	 these	experiments	we	 found	a	decrease	 in	 the	expression	of	 the	GluN1	 subunit	
(Fig.	3A),	as	well	as	a	decrease	 in	the	phosphorylation	of	GluN1	at	serine	896	(Fig.	3A),	 in	the	
PFC	 of	 TAAR1-KO	 mice.	 No	 changes	 in	 the	 serine	 897	 residue	 of	 the	 same	 subunit	 were	
observed	(Fig.	3A).	Furthermore,	a	decrease	in	the	expression	of	GluN2B	was	also	documented	
(Fig.	3B),	with	no	changes	observed	in	phospho-GluN2B	(serine	1303)	(Fig.	3B)	or	GluN2A	levels	
(Fig.	 3B).	 In	 contrast	 to	GluN1	and	GluN2B	NMDA	 receptor	 subunits,	AMPA	 receptor	 subunit	
GluA1	 levels	 and	phosphorylation	 status	 (Serine	831)	were	not	 changed	 in	mutants	 (Fig.	 3C).	
Similarly,	 the	 levels	 of	 PSD-95,	 a	 postsynaptic	 protein	 critically	 involved	 in	 the	 proper	
organization	 of	 postsynaptic	 structure	 and	 integrity	 (Gardoni	 and	 Di	 Luca,	 2006),	 were	 not	
altered	 by	 TAAR1	 deficiency	 (Fig.	 3C).	 These	 data	 demonstrate	 significant	 alterations	 in	 the	
composition	 of	 cortical	 NMDA	 receptors	 further	 supporting	 NMDA	 receptor	 dysfunction	
observed	in	the	PFC	of	TAAR1-KO	mice	in	electrophysiological	experiments.	In	addition,	to	test	








To	unveil	 the	behavioral	 consequences	of	TAAR1	deficiency	 leading	 to	altered	cortical	NMDA	
receptor	 function,	 we	 first	 evaluated	 the	 cognitive	 functions	 of	 TAAR1-KO	 mice	 in	 a	 Fixed	
Interval-Peak	 Interval	 test	 (Matell	 and	 Meck,	 2000).	 The	 automated	 protocols	 allowed	 the	
testing	of	mice	in	home	cages	for	24	hours	per	day	for	several	days	to	collect	a	massive	amount	
of	 data	 with	 less	 variability	 by	 monitoring	 mouse	 behavior	 according	 to	 their	 physiological	
sleep-wake	 cycle.	 In	 particular,	 this	 test	 allows	 reliable	 assessment	 of	 various	 aspects	 of	
cognitive	 functions	of	mice	 in	home	cage	environment.	All	mice	 received	3	days	of	magazine	
training	 to	 familiarize	 the	 mice	 with	 reward	 delivery.	 Overall,	 the	 animals	 managed	 to	 gain	
more	than	160	pellets	per	day	before	switching	to	the	Training	phase.	During	the	training	phase	
(Fig.	4A,	B),	the	nose-poke	(NP)	activity	was	monitored;	such	activity	has	a	circadian	oscillation	
along	 the	 days	 according	 to	 the	 light/dark	 (LD)	 cycle	 (Fig.	 4C).	 The	 amount	 of	 activity	 was	
computed	with	1	hour	bin	 for	each	subject,	and	 the	periodicity,	computed	with	a	periodic	 fit	
(see	Materials	and	Methods),	was	perfectly	entrained	with	the	LD	cycle	(Fig.	4C,	boxplots	above	
the	 graph).	 The	 curves	 showed	 a	 significant	 increase	 in	 the	 NP	 activity	 for	 TAAR1-KO	 mice	
during	the	dark	phase,	suggesting	hyperactivity	during	the	night,	but	not	during	the	light	phase	




how	 to	 get	 the	 reward,	 TAAR1-KO	 mice	 performed	 worse	 than	 WT	 mice,	 shown	 as	 the	
difference	in	the	slope	of	the	cumulative	curve	of	error	trials	(Fig.	4E).	Later,	when	the	test	was	
learned,	 the	 slopes	 between	 the	 two	 groups	 were	 similar	 (Fig.	 4E).	 To	 further	 assess	 the	
changes	of	the	performance	over	the	light/dark	cycle,	we	analyzed	the	Actual	Inter-Trials	(AIT)	
durations	between	two	consecutive	trials.	These	intervals	occur	due	to	the	delay	of	the	mouse	
to	 initiate	 a	 trial	 and	have	been	used	 as	 a	measurement	of	 impulsivity	 (Matell	 and	Portugal,	







from	the	 first	day	 to	 the	 fifth	day	of	 the	experiment.	Although	there	was	an	 improvement	 in	
STOP	responses	between	the	first	and	 last	days	 in	both	TAAR1-KO	and	WT	mice,	a	significant	
difference	 between	 the	 two	 genotypes	 remained	 throughout	 the	 experiment	 (Fig.	 4H).	
Moreover,	 the	 Peak	 times,	 which	 reflect	 the	 accuracy	 in	 the	 timing	 perception,	 were	
significantly	 different	 between	 the	 genotypes	 (Fig.	 4I)	 and	 showed	 significant	 changes	 over	
time.	 These	 changes	 in	 the	 temporal	 precision	 and	 accuracy	 (Fig.	 4G-I)	 are	 considered	 the	
hallmarks	of	the	clock-speed	adjustment	(Matell	et	al,	2006).	The	right	hopper	was	assigned	to	
the	 activation	 of	 the	 trial	 after	 a	 refractory	 period,	 the	 AIT.	 To	 further	 analyze	 impulsive	
behavior	in	these	mice,	we	analyzed	the	average	number	of	NPs	in	the	right	hopper	during	the	
AITs,	after	the	release	of	the	reward	and	along	the	24	hours	because	this	type	of	observation	
has	 also	 been	 considered	 to	 be	 related	 to	 impulsivity	 (Dalley	 et	 al,	 2004).	 According	 to	 the	
decrease	in	the	AITs,	we	observed	a	significant	increase	in	the	number	of	nose	pokes	in	KO	mice	
compared	 to	 control	 animals	 (Fig.	 4J).	 Thus,	 we	 observed	 several	 indications	 of	 cognitive	
abnormalities	 in	 mutant	 mice	 further	 supporting	 altered	 cortical	 function	 in	 mice	 lacking	
TAAR1.	
	TAAR1	agonists	reduce	impulsivity	in	mice		
To	 test	 whether	 we	 could	 modulate	 behaviors	 generally	 related	 to	 mPFC	 function	 by	
pharmacological	activation	of	TAAR1,	we	examined	the	effects	of	two	TAAR1	selective	ligands	
(Revel	 et	 al,	 2013),	 a	 full	 agonist	 and	 a	 partial	 agonist,	 RO5166017	 and	 RO5203648,	
respectively,	 (Revel	 et	 al,	 2011;	 Revel	 et	 al,	 2012)	 in	 a	 classic	 Skinner’s	 schedule	 of	
reinforcement,	 FI-30	 seconds	 (Sagvolden	 et	 al,	 1983)	 in	 C57Bl/6J	 mice.	 This	 behavioral	
paradigm	provides	a	measure	of	impulsivity	that	is	believed	to	be	at	least	in	part	controlled	by	
cortical	 function	 (Bari	 and	Robbins,	 2013).	 	 After	 training	with	 increasing	periods	of	 intervals	
(from	3	 seconds	 to	 30	 seconds),	 the	 test	 started.	 C57Bl/6J	mice	were	 injected	with	 saline	or	
TAAR1	 agonists	 before	 the	 session,	 and	 two	 parameters	 were	 scored	 as	 a	 measure	 of	
impulsivity,	 including	premature	correct	 responses	and	 the	post	 reinforcement	pause	 (Berger	
and	Sagvolden,	1998).	Pretreatment	with	RO5166017	and	RO5203648	decreased	the	number	of	
correct	 premature	 responses	 (Fig.	 5A,	 C).	 By	 analyzing	 the	 post-reinforcement	 pause,	 we	










(Fig.	 S3A,	B)	 and	 RO5203648	 (Fig.	 S3C,	D)	 did	 not	 change	 significantly	 these	 parameters.	 All	





NMDA	 receptor	 activity	 indicating	 that	 TAAR1	 can	 modulate	 PFC-related	 processes	 and	
behaviors.	 First,	we	observed	 that	 TAAR1	 is	 expressed	 in	 the	 PFC,	 primarily	 in	 the	 pyramidal	
neurons	 of	 layer	 V,	 supporting	 and	 extending	 the	 previous	 evidence	 on	 TAAR1	 mRNA	
expression	 in	 the	 frontal	 lobe	 (Di	 Cara	 et	 al.,	 2011).	 Furthermore,	 by	 using	 patch	 clamp	
recording	in	the	pyramidal	neurons	of	layer	V,	we	found	an	altered	response	upon	stimulation	
of	the	afferent	fibers.	From	the	analysis	of	the	eEPSC	we	noted	that	there	was	an	increase	of	
the	current	 that	potentially	may	suggest	an	 increase	 in	AMPA	receptor	activity.	 	At	 the	same	
time,	 a	 decrease	 of	 the	 current	 kinetic	 may	 suggest	 a	 decrease	 in	 NMDA	 receptor	 activity.	
Moreover,	we	found	a	decreased	NMDA/AMPA	receptors	ratio,	which	may	indicate	glutamate	
NMDA	 receptor	 hypofunction.	 The	 analysis	 of	 the	 mEPSCs	 mediated	 by	 NMDA	 revealed	 a	
strong	 reduction	 in	 the	 frequency	 and	 amplitude	 of	 the	 events,	 indicating	 indeed	 that	
postsynaptic	NMDA	receptors	 in	these	 layers	were	 less	active.	
dysfunction	of	layer	V	pyramidal	neurons	in	the	PFC	has	been	correlated	with	cognitive	deficits	
(Seamans	 et	 al,	 2001).	 It	 is	 known	 that	NMDA	 receptor	 function	 can	negatively	 affect	AMPA	
current	and	spine	formation/morphology	at	pre-	and	post-synaptic	side	(Ultanir	et	al,	2007).		In	
particular,	 NR2B	 subunit	was	 shown	 to	 inhibit	 AMPA	 receptor	 surface	 expression	 (Kim	 et	 al,	
2005).	 Thus,	 the	 increase	 of	 AMPA	 current	 observed	 in	 our	 experiments	may	 be	 potentially	
explained	by	the	reduction	of	the	NR2B	subunit	that	finely	regulates	AMPA	receptor	availability	
at	 the	postsynaptic	 side	membrane	without	 significant	changes	 in	 the	 total	amount	of	AMPA	
receptor	 protein.	 Furthermore,	 the	 decrease	 in	 NMDA	 receptor	 function	 may	 alter	 the	
presynaptic	 side	 increasing	 the	 release	of	 glutamate	 from	synaptic	 vesicles	and	 consequently	
the	AMPA	current.		












in	 	 home	 cage	 environment	 in	 a	 Fixed	 Interval-Peak	 Interval	 test	 (Matell	 et	 al,	 2000).	
Particularly,	 we	 attempted	 to	 unveil	 whether	 and	which	 type	 of	 cognitive	 deficits	may	 arise	
from	TAAR1	ablation.	We	found,	 in	 fact,	 that	 the	 lack	of	TAAR1	per	sè	did	not	cause	a	global	
cognitive	 impairment	 but	 these	 mice	 were	 making	 more	 errors	 during	 the	 first	 period	 of	
learning,	 indicating	a	 small	 initial	deficit	 in	 learning.	However,	 even	more	 interestingly,	 these	
mice	displayed	an	incorrect	time	of	perception,	as	indicated	by	the	analysis	of	the	peaks	during	
probe	trials	(Coull	et	al.,	2011).	Timing	is	a	cognitive	property	well	conserved	between	species,	
and	 the	 PFC	 plays	 an	 essential	 role	 in	mediating	 the	 correct	 timing	 perception	 (Meck	 et	 al,	
2008).	 By	 analyzing	 the	 STOP	 responses	 during	 the	 probes	 trials,	 it	 emerged	 that	 TAAR1-KO	
mice	have	delayed	average	STOP	responses.	 It	 is	also	clear	 from	Fig.	4J	 that	 the	shape	of	 the	
nose-poke	distribution	between	 the	 two	genotypes	was	different,	with	a	wider	difference	on	
the	first	day	that	was	still	evident	on	the	last	day.	This	perseverative	behavior,	defined	as	a	lack	
of	 suppression	 of	 previously	 engaged	 and	 ineffective	 behavior,	 is	 a	 sign	 of	 impairment	 in	
cognitive	 flexibility	 and	 could	 be	 modeled	 by	 pharmacological	 treatments	 that	 alter	 PFC	
functions	 as	 well	 as	 by	 frontal	 cortex	 lesions	 (Floresco	 et	 al,	 2009).	 Notably,	 this	 particular	






a	 validated	 experimental	 paradigm	 for	 impulsivity	 in	 mice	 (Sagvolden	 et	 al,	 1983),	 we	
demonstrated	 that	 two	 selective	 TAAR1	 agonists	 (Revel	 et	 al,	 2013)	 reduced	 impulsive	





al,	 2013).	 Interestingly,	 TAAR1-KO	 mice	 are	 more	 prone	 to	 the	 addictive	 properties	 of	
methamphetamine,	ethanol	and	MDMA	(Achat-Mendes	et	al,	2012;	Di	Cara	et	al,	2011;	Lynch	
et	al,	2013),	while	recent	reports	from	different	groups	have	demonstrated	that	TAAR1	full	and	
partial	 agonists	 reduce	 cocaine	 conditioned	 place	 preference	 (CPP),	 self-administration	 and	
relapse	 (Pei	 et	 al,	 2014;	 Revel	 et	 al,	 2012;	 Thorn	 et	 al,	 2014a;	 Thorn	 et	 al,	 2014b).	 Since	
impulsivity	 is	 considered	 to	 be	 a	 specific	 trait	 in	 the	 pathophysiology	 of	 drug	 addiction,	 it	 is	
possible	 that	TAAR1	can	 reduce	addictive	behaviors	 in	part	 through	PFC-related	mechanisms.	
Certainly,	 more	 studies	 are	 necessary	 to	 directly	 connect	 the	 observed	 PFC	 deficits	 and	 the	
impulsive/perseverative	phenotype	of	mutant	animals.	 	Particularly,	since	TAAR1	 is	expressed	
in	 both	 the	 VTA	 dopaminergic	 nuclei	 (Lindemann	 et	 al,	 2008)	 and	 in	 the	 PFC	 (Fig.	 1A),	 the	
development	of	a	conditional	region-selective	mutant	mouse	 line	would	be	critical	to	address	
this	question.		
With	 respect	 to	 the	 mechanism	 by	 which	 TAAR1	 could	 modulate	 cortical	 glutamate	
NMDA	receptor-related	transmission	and	functions,	several	possibilities	should	be	considered.		
It	 is	 known	 that	 TAAR1	 exerts	 potent	 modulatory	 influence	 over	 mesolimbic	 dopaminergic	
system	 likely	 via	D2	dopamine	 receptor-TAAR1	heterodimerization	 (Espinoza	 et	al,	 2011)	and	
similar	mechanisms	 could	 be	 involved	 in	 the	 regulation	of	 cortical	 dopamine	 transmission	 as	
well.	 In	 this	 case,	 the	 observed	 alterations	 in	 cortical	 glutamate	 transmission	 could	 be	
secondary	to	alterations	in	cortical	dopamine	system.		Alternatively,	since	TAAR1	is	expressed	
in	 the	 layer	 V	 of	 PFC,	 where	 significant	 deficiency	 in	 NMDA	 receptor-mediated	 glutamate	
transmission	was	observed,	it	is	possible	that	glutamate	transmission	deficits	could	be	a	direct	
consequence	 of	 the	 absence	 of	 cortical	 TAAR1.	 Intriguingly,	 a	 recent	 report	 indicated	 that	
TAAR1	can	modulate	the	function	of	the	glutamate	transporter	EAAT2	leading	to	alterations	in	
glutamate	 clearance	 suggesting	 a	 direct	 connection	 between	 TAAR1	 and	 glutamate	





In	 conclusion,	 we	 document	 here	 an	 abnormal	 PFC	 function	 in	 mice	 lacking	 TAAR1.	
Specifically,	we	found	NMDA	receptor-mediated	glutamate	transmission	deficiency	in	the	PFC,	
likely	 leading	 to	 the	aberrant	perseverative	and	 impulsive	behaviors	 that	are	observed	 in	 the	
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Fig.	 1.	 Deletion	 of	 TAAR1	 increases	 the	 amplitude	 and	 kinetics	 of	 evoked	 excitatory	
postsynaptic	currents	in	layer	V	pyramidal	neurons	of	the	frontal	cortex.		
(A,	right	panel)	The	expression	of	red	fluorescent	protein	dsRed	under	the	rat	TAAR1	promoter	
in	 	 the	 layer	V	of	PFC	of	 transgenic	TAAR1	KO	dsRed	 rats.	Representative	 images	were	 taken	
using	 and	 the	 overlay	 of	 the	 bright-field	 and	 dsRed	 channel	 from	 the	 layer	 V	 of	 PFC	 of	
transgenic	TAAR1	KO	dsRed	rats	(A,	right	panel,	bottom)	and	WT	controls	(A,	right	panel,	top)	.	
(A,	 left	 panel)	 Nissl-stained	 coronal	 section	 of	 a	 brain	 slice	 containing	 the	medial	 prefrontal	
cortex	 (mPFC;	 box)	 in	 which	 patch	 clamp	 experiments	 were	 performed	 (A).	 Current-clamp	
protocol	and	representative	traces	of	action	potentials	induced	by	the	injection	of	200	pA	(B).	
Action	potential	 frequency	vs.	 injected	current	 relationship	 (F/I	 curve)	and	resting	membrane	
potential	(C),	maximal	firing	rate,	mean	firing	frequency,	current	threshold	and	input	resistance	
(D)	were	measured	in	WT	and	TAAR1-KO	mice.	(E)	Representative	traces	of	evoked	excitatory	
postsynaptic	 currents	 from	 layer	 V	 pyramidal	 neurons	 recorded	 upon	 stimulation	 of	 layer	 III	
neuron	 fibers	 in	 both	 WT	 and	 TAAR1-KO	 mice.	 (F)	 Amplitude,	 rise	 time	 and	 decay	 time	 of	
evoked	 excitatory	 postsynaptic	 currents	 were	 altered	 in	 KO	 compared	 to	WT	 neurons.	 Data	




Representative	 traces	 of	 evoked	 AMPA	 (-70	mV)	 or	 NMDA	 (+60	mV)	 excitatory	 postsynaptic	
currents	from	layer	V	pyramidal	neurons	recorded	upon	stimulation	of	 layer	 III	 fibers	(A).	The	


















fixed	 to	 10	 seconds.	 The	 probability	 of	 trial	 to	 occur	 in	 “L”	 location	 is	 100%	 (P(L)=1).	 Peak-





for	 WT	 and	 TAAR1-KO	 mice	 (C).	 The	 circadian	 trend	 of	 the	 error	 rate	 (D)	 was	 significantly	
different	 within	 genotype	 and	 between	 light	 and	 dark	 phases	 (Two-way	 ANOVA	 for	 WT:	
F(1,143)=40.67,	 p<0.001;	 for	 KO:	 F(1,143)=64.96,	 p<0.001),	 but	 not	 between	 genotypes	
(F(1,287)=0.47,	 p=0.49)	 as	 summarized	 in	 the	 histogram	 above	 the	 curve.	 Cumulative	
distribution	function	(CDF)	of	the	error	rate	along	the	time	(E).	Significant	difference	of	the	total	
errors	between	genotypes	during	the	first	three	hours	of	the	first	dark	phase	(19-21),	p=0.04.	
No	difference	between	genotypes	 in	the	subsequent	 intervals	 (p≥0.05).	Analysis	of	the	Actual	
Inter	 trials	 (AITs)	 (F)	 revealed	 a	 difference	 between	 genotypes	 along	 24	 hours	 (Two-way	




effect	was	also	significant	 (F(1,59)=5.35,	p=0.02).	There	was	no	difference	 in	 the	START	 time.	
Normalized	 response	 rate	 during	 probe	 trials	 in	 the	 first	 and	 last	 days	 (H).	 Peak	 times	were	
significantly	 different	 between	 genotypes	 (F(1,59)=4.19,	 p=0.04)	 and	 showed	 significant	
changes	over	time	(F(4,56)=3.05,	p=0.02)	(I).	The	right	nose	pokes	during	the	AITs,	along	the	24	






Fig.	 5.	 Systemic	 administration	 of	 selective	 TAAR1	 agonists	 reduces	 impulsivity	 in	 a	 FI	 30	




mg/kg	 for	 RO5203648.	 Activation	 of	 TAAR1	 receptors	 did	 not	 affect	 significantly	 post-
reinforcement	pause	(F(3,28)=1.967	p=0.14;	F(3,26)=2.506	p=0.08,	RO5166017	and	RO5203648	
respectively)	(B,D).	All	the	data	are	shown	as	mean±SEM.	N=12	per	group.	RO5203648	at	dose	
0.3	mg/kg	was	able	to	reduce	the	number	of	correct	premature	responses	in	WT	(p<0.05)	but	
not	in	TAAR1-KO	animals	(E).	Similarly,	RO5203648	increased	post-reinforcement	pause	in	WT	
(p<0.01)	but	not	in	TAAR1-KO	mice	(F).	All	the	data	are	shown	as	mean±SEM.	N=10	(WT)	and	8	
(KO)	per	group	.	*,	p<0.05;	**,	p<0.01.	One	way	ANOVA	with	Bonferroni	post	hoc	test.	
